Acumen Pharmaceuticals, Inc.ABOSNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating

Buy

7 analysts·Limited coverage

100%

Rating Distribution

Strong Buy

00%

Buy

7100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 169% higher.

Bear Case

$7.00

+169%

Consensus

$7.00

+169%

Bull Case

$7.00

+169%

Price Range7 analysts

Low

Consensus

High

$7.00

Current Target

Current Price

$2.60

Upside to Target

$4.40

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.65(3 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev—

EPS—

FY2028

Rev—

EPS—

FY2029

Rev+111.80%

EPS—

Earnings Surprises

Beat rate:42%(5/12 quarters)

Avg surprise:-3.1%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jul 25, 2024Citigroup

Acumen initiated with a Buy at Citi

Target:$7.00

+105.3%from $3.41

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance